Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer

Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer

Significant improvement in targeted therapy for colorectal cancer (CRC) has occurred over the past few decades since the approval of the EGFR inhibitor cetuximab. However, cetuximab is used only for patients possessing the wild-type oncogene KRAS, NRAS, and BRAF, and even most of these eventually ac...

Full description

Bibliographic Details
Main Authors: Yoon Sun Park, Joseph kim, Yea Seong Ryu, Jai-Hee moon, Yu Jin shin, Jeong Hee kim, Seung-Woo hong, Soo-A jung, Seul lee, Seung-Mi kim, Dae Hee lee, Do Yeon kim, Hyeseon yun, Ji-Eun you, Dong Il yoon, Chul Hee kim, Dong-In koh, Dong-Hoon jin
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Cancer Biology & Therapy
Subjects:
pim1
pik3ca
mutant kras
colorectal cancer
predictive marker
Online Access:http://dx.doi.org/10.1080/15384047.2023.2246208

Internet

http://dx.doi.org/10.1080/15384047.2023.2246208

Similar Items